Cite
Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021;23(1):77-90doi: 10.1016/S1470-2045(21)00604-5.
Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, E., Zaucha, R., Furuse, J., Abou-Alfa, G. K., El-Khoueiry, A. B., Melero, I., Begic, D., Chen, G., Neely, J., Wisniewski, T., Tschaika, M., & Sangro, B. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology, 23(1), 77-90. https://doi.org/10.1016/S1470-2045(21)00604-5
Yau, Thomas, et al. "Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial." The Lancet. Oncology vol. 23,1 (2022): 77-90. doi: https://doi.org/10.1016/S1470-2045(21)00604-5
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. PMID: 34914889.
Copy
Download .nbib